Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
Aged
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Brain Neoplasms
/ drug therapy
Cetuximab
/ administration & dosage
Chemoradiotherapy
Cisplatin
/ administration & dosage
Female
Fluorouracil
/ administration & dosage
Humans
Induction Chemotherapy
Lung Neoplasms
/ drug therapy
Neoplasm, Residual
Nivolumab
/ therapeutic use
Parotid Neoplasms
/ diagnostic imaging
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Treatment Failure
Treatment Outcome
Brain metastasis
Head and neck
Immune checkpoint inhibitor
Squamous cell carcinoma
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
18
07
2018
revised:
29
08
2018
accepted:
17
10
2018
pubmed:
18
11
2018
medline:
29
1
2020
entrez:
17
11
2018
Statut:
ppublish
Résumé
CheckMate 141, an open-label, randomized phase III trial of nivolumab, indicated that treatment with nivolumab prolonged overall survival of patients with platinum-refractory, recurrent head and neck squamous cell carcinoma. Herein, we describe a case of brain metastasis of parotid carcinoma in which a good response was achieved after nivolumab treatment. The patient was a 67-year-old woman with parotid carcinoma (cT4bN0M0) who received induction chemotherapy followed by chemoradiation. Computed tomography and magnetic resonance imaging performed 10 weeks after the primary treatment revealed a residual tumor and brain and lung metastases. Thereafter, chemotherapy comprising cisplatin, 5-FU, and cetuximab was performed. Unfortunately, the tumor volume increased 5 months after chemotherapy, after which she received immunotherapy with biweekly nivolumab. After six cycles of nivolumab administration, the brain and lung metastases shrank markedly. Nivolumab had an intracranial effect in the patient with brain metastases of parotid carcinoma. This case report highlights the efficacy of nivolumab in the management of head and neck cancer with brain metastasis.
Identifiants
pubmed: 30442438
pii: S0385-8146(18)30644-8
doi: 10.1016/j.anl.2018.10.003
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Cetuximab
PQX0D8J21J
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-817Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.